Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on minimally invasive surgical technologies for sacropelvic disorders, including sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, spinopelvic and sacropelvic fixation, and pelvic trauma. This news page aggregates company press releases and market updates related to SIBN stock and SI-BONE’s sacropelvic platform.
Investors following SI-BONE news can expect regular updates on quarterly and annual financial results, preliminary revenue announcements, and changes to financial guidance. Recent communications have highlighted double-digit worldwide and U.S. revenue growth, gross margin performance, adjusted EBITDA trends, and cash and cash equivalents. The company also reports operational metrics such as the number of active U.S. physicians using its technologies and revenue per sales territory.
Beyond earnings, SI-BONE’s news flow includes information on reimbursement developments, such as New Technology Add-on Payments and other payment designations for procedures involving products like iFuse TORQ TNT and iFuse Bedrock Granite. The company also issues 8-K-linked press releases covering leadership and board changes, including retirements, consulting agreements, and commercial leadership transitions.
Another recurring theme in SI-BONE news is participation in healthcare and medtech investor conferences hosted by firms such as Piper Sandler, Morgan Stanley, Canaccord Genuity, Truist Securities, and Goldman Sachs. These events often feature fireside chats or presentations where management discusses sacropelvic technologies, clinical evidence, and financial performance, with webcasts made available through the investors section of SI-BONE’s website.
For anyone tracking SIBN, this page offers a centralized view of SI-BONE’s earnings releases, preliminary updates, conference appearances, and other company announcements related to its sacropelvic surgical technology platform.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in musculoskeletal disorder solutions, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 11 at 3:30 p.m. ET. This event will showcase SI-BONE's innovations, particularly the iFuse Implant System, designed for minimally invasive surgeries targeting SI joint pain, a contributor to chronic low back pain affecting up to 30% of patients. More than 55,000 SI joint fusion procedures have been performed using this technology. Live access to the presentation will be available on the company’s website.
SI-BONE, a leader in musculoskeletal disorder treatments, will report its second quarter 2021 financial results on August 2, 2021, after market close. A conference call will follow at 1:30 p.m. PT, which investors can join by calling (866) 470-1968. The company's iFuse Implant System has been pivotal in treating SI joint issues, supported by extensive clinical evidence. More than 55,000 procedures have been conducted by over 2,300 surgeons. SI-BONE aims to leverage its market position for further commercial device development.
SI-BONE, Inc. (Nasdaq: SIBN) announced on July 14, 2021, that Centene Corporation has implemented a positive coverage policy for the iFuse Implant System, a treatment for chronic sacroiliac joint pain. This policy recognizes minimally invasive SI joint fusion as a medically necessary procedure when specific criteria are met, enhancing patient access. Centene serves over 25 million members and aims to improve treatment availability for low-income individuals. The policy reflects extensive clinical evidence supporting the safety and effectiveness of the iFuse system.
SI-BONE, Inc. (Nasdaq: SIBN) has released promising 24-month results from the SALLY study, showcasing the efficacy of the iFuse-3D™ Implant System in treating sacroiliac joint pain. The study reported a significant decline in opioid use from 59% to 18% and consistent improvements in patient function and quality of life. This follows earlier studies endorsing the iFuse implant's safety and effectiveness. The iFuse-3D implant, designed for enhanced bone integration, is expected to further bolster the company's market position in the medical device sector.
SI-BONE, Inc. (SIBN) has launched the SI-BONE SImulator™, a revolutionary training simulation system for surgeons. This innovative platform is designed to enhance the learning of SI-BONE sacropelvic procedures, including iFuse procedures, using radiation-free technology. The SImulator can be utilized in various settings without traditional imaging equipment, making it accessible and portable. The collaboration with Medability has resulted in a versatile training tool that supports both group and individual training sessions and focuses on patient-specific anatomies.
SI-BONE, Inc. (Nasdaq: SIBN) announced national reimbursement for the iFuse-3D Implant System™ by the French Health Ministry, effective June 1, 2021, for five years. This follows a positive opinion from the Haute Autorité de Santé recognizing the implant's therapeutic benefits for sacroiliac joint dysfunction. The implant is the first 3D-printed titanium solution for SI joint fusion, designed for effective bony integration. With reimbursement confirmed, patient access in France improves, allowing surgeons to leverage this technology for various pelvic and spinal conditions.
SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2021 JMP Securities Life Sciences Conference. The company is set to present on June 17 at 2:30 p.m. ET. Interested parties can access a live and archived webcast on the company’s website. SI-BONE specializes in minimally invasive surgery of the SI joint with its iFuse Implant System, which has demonstrated effectiveness for treating chronic low back pain associated with sacroiliac joint dysfunction.
SI-BONE, Inc. (SIBN) reported Q1 2021 revenue of $20.4 million, marking a 22% increase from Q1 2020. U.S. revenue reached $18.8 million, up 23% year-over-year. The company launched the iFuse-TORQ implant to address pelvic trauma needs and has transitioned its leadership team, appointing Laura Francis as CEO. Operating loss narrowed to $11.6 million from $11.9 million in 2020. Despite a cautious outlook due to COVID-19, SIBN anticipates 2021 revenue of $92 million to $94 million, projecting a 25% to 28% growth.
SI-BONE, a medical device company focused on sacropelvic disorders, will participate in two key events: the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021, and the 2021 Bank of America Health Care Conference on May 12, 2021. During the Truist Securities event, management will host a Fireside Chat at 2:40 p.m. ET, and at the Bank of America Conference, they will present at 8:00 a.m. ET. Interested parties can view live and archived webcasts on the company’s website.
SI-BONE, Inc. (SIBN) announced significant leadership changes, appointing Anshul Maheshwari as Chief Financial Officer effective April 20, 2021. The transition also includes Laura Francis taking over as CEO, while Jeff Dunn remains Executive Chairman. Maheshwari brings over 15 years of experience, including his role at Varian Medical Systems. Additionally, Helen Loh and Laura Francis are new Board members, expected to enhance SI-BONE's strategy and marketing efforts. These changes aim to strengthen the company's growth and operational capabilities.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
